Table 2a. Preoperative characteristics for patients suitable for AS according to the Toronto criteria – by centre.
| Total | Cambridge | Melbourne | Vancouver | |
|---|---|---|---|---|
| Years of data | 1995–2010 | 2005–2010 | 2003–2010 | 1995–2010 |
| N (total RP) | 2329 | 700 | 790 | 839 |
| N (total AS) | 800 (34.3%) | 267 (40%) | 187 (31%) | 190 (32%) |
| Age (years) | ||||
| Median (IQR) | 61 (56.7−65) | 61 (39−73) | 60 (42−74) | 61 (43−79) |
| PSA (ng ml−1) | ||||
| Median (IQR) | 5.8 (4.7−7.4) | 6.4 (0.5−10) | 5.5 (0.3−10) | 5.5 (0.5−10) |
| Clinical stage | ||||
| cT1 | 570 (71.3%) | 206 (77%) | 149 (80%) | 109 (58%) |
| cT2a | 230 (28.7%) | 59 (23%) | 38 (20%) | 80 (42%) |
| PSA density a | ||||
| Median (IQR) | 0.1 (0.086−0.151) | 0.108 (0.011−0.816) | 0.114 (0.014−0.315) | 0.11 (0.012−0.371) |
| Biopsy cores taken | ||||
| Median (range) | 10 (2−30) | 12 (4−30) | 11 (4−30) | 8 (2−13) |
| Number of positive cores | ||||
| Median (IQR) | 2 (1−4) | 2 (1−14) | 3 (1−12) | 2 (1−8) |